|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
156,320,000 |
Market
Cap: |
6.26(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$20.26 - $43.27 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Cerevel Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co.'s programs: Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype; Darigabat, which is a PAM that selectively targets the alpha-2/3/5 subunits of the GABAA receptor; Tavapadon, which is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of early- and late-stage Parkinson's disease; and CVL-871, which is a selective dopamine D1/D5 receptor partial agonist specifically designed to achieve a level of partial agonism.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
17,422,701 |
18,847,701 |
Total Buy Value |
$0 |
$0 |
$397,510,553 |
$447,385,553 |
Total People Bought |
0 |
0 |
6 |
6 |
Total Buy Transactions |
0 |
0 |
6 |
7 |
Total Shares Sold |
150,000 |
381,632 |
659,132 |
1,300,893 |
Total Sell Value |
$6,252,285 |
$15,864,974 |
$23,446,852 |
$43,726,088 |
Total People Sold |
1 |
8 |
8 |
10 |
Total Sell Transactions |
3 |
17 |
27 |
50 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Coles N Anthony |
|
|
2024-04-01 |
4 |
AS |
$42.33 |
$2,116,640 |
D/D |
(50,000) |
15,638 |
|
-5% |
|
Coles N Anthony |
|
|
2024-04-01 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
65,638 |
|
- |
|
Coles N Anthony |
|
|
2024-03-04 |
4 |
AS |
$41.01 |
$2,050,550 |
D/D |
(50,000) |
15,638 |
|
-3% |
|
Coles N Anthony |
|
|
2024-03-04 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
65,638 |
|
- |
|
Coles N Anthony |
|
|
2024-02-29 |
4 |
AS |
$41.16 |
$2,057,890 |
D/D |
(50,000) |
15,638 |
|
-2% |
|
Coles N Anthony |
|
|
2024-02-29 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
65,638 |
|
- |
|
Edelman Joseph |
Director |
|
2024-02-20 |
4 |
GD |
$0.00 |
$0 |
I/I |
170,317 |
0 |
|
- |
|
Renger John |
Chief Scientific Officer |
|
2024-02-07 |
4 |
S |
$41.54 |
$89,777 |
D/D |
(2,161) |
6,370 |
|
3% |
|
Coles N Anthony |
|
|
2024-02-07 |
4 |
S |
$41.54 |
$104,110 |
D/D |
(2,506) |
15,638 |
|
3% |
|
Renger John |
Chief Scientific Officer |
|
2024-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,020 |
8,531 |
|
- |
|
Coles N Anthony |
|
|
2024-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,440 |
18,144 |
|
- |
|
Coles N Anthony |
|
|
2024-01-02 |
4 |
AS |
$42.24 |
$2,111,815 |
D/D |
(50,000) |
2,704 |
|
-0% |
|
Coles N Anthony |
|
|
2024-01-02 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
|
- |
|
Tregoning Kathleen |
See Remarks |
|
2023-12-26 |
4 |
OE |
$10.05 |
$31,658 |
D/D |
3,150 |
10,666 |
|
- |
|
Sanchez Ramiro |
Chief Medical Officer |
|
2023-12-26 |
4 |
AS |
$42.47 |
$424,700 |
D/D |
(10,000) |
14,673 |
|
-0% |
|
Sanchez Ramiro |
Chief Medical Officer |
|
2023-12-26 |
4 |
OE |
$3.50 |
$35,000 |
D/D |
10,000 |
24,673 |
|
- |
|
Dipietro Kenneth |
Chief Human Resources Officer |
|
2023-12-22 |
4 |
S |
$41.45 |
$331,608 |
D/D |
(8,000) |
24,663 |
|
-1% |
|
Dipietro Kenneth |
Chief Human Resources Officer |
|
2023-12-22 |
4 |
OE |
$3.50 |
$28,000 |
D/D |
8,000 |
32,663 |
|
- |
|
Akamine Scott |
Chief Legal Officer |
|
2023-12-20 |
4 |
S |
$41.42 |
$292,945 |
D/D |
(7,072) |
7,237 |
|
-3% |
|
Dipietro Kenneth |
Chief Human Resources Officer |
|
2023-12-20 |
4 |
S |
$41.42 |
$259,144 |
D/D |
(6,256) |
24,663 |
|
-3% |
|
Tregoning Kathleen |
See Remarks |
|
2023-12-20 |
4 |
S |
$41.42 |
$260,469 |
D/D |
(6,288) |
7,516 |
|
-3% |
|
Sanchez Ramiro |
Chief Medical Officer |
|
2023-12-20 |
4 |
S |
$41.42 |
$420,528 |
D/D |
(10,152) |
14,673 |
|
-3% |
|
Bodenrader Mark |
See Remarks |
|
2023-12-20 |
4 |
S |
$41.42 |
$326,788 |
D/D |
(7,889) |
17,724 |
|
-3% |
|
Altschuller Susan |
Chief Financial Officer |
|
2023-12-20 |
4 |
S |
$41.42 |
$571,972 |
D/D |
(13,808) |
16,913 |
|
-3% |
|
Burgess Paul D. |
See Remarks |
|
2023-12-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,847 |
45,727 |
|
- |
|
181 Records found
|
|
Page 1 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|